Quarterly report
Open the filing on sec.gov
Incannex Healthcare Inc. (IXHL)
Nasdaq: IXHL · Pharmaceutical Preparations · filing with the SEC since 2021
The companyfiscal 2026, as filed
Revenue$0.00-100.0%
Net income-$19.3M+58.8%
Earnings per share$-1.66+95.9%
Operating cash flow-$12.9M-2.8%
Cash$67.7M+350.2%
Debtn/a
Shareholders’ equity$67.4M+403.2%
Shares, diluted11.7M+915.1%
Return on equity-28.6%
The recordfrom its filings
Filings in 202631
Newest filingNov 12 · 10-Q
Annual reportSep 25, 2026
Quarterly reportNov 12, 2026
Next report due10-Q by Feb 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted7
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$14.8MCash from operations -$3.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Annual report to shareholders
Open the filing on sec.gov
Extra proxy material
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Annual report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.